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Lipopolysaccharide (LPS) is a component of the outer membrane of almost all
Gram-negative bacteria and consists of lipid A, core sugars, and O-antigen. LPS is
recognized by Toll-like receptor 4 (TLR4) and MD-2 on host innate immune cells
and can signal to activate the transcription factor NFκB, leading to the production of
pro-inflammatory cytokines that initiate and shape the adaptive immune response. Most
of what is known about how LPS is recognized by the TLR4-MD-2 receptor complex on
animal cells has been studied using Escherichia coli lipid A, which is a strong agonist
of TLR4 signaling. Recent work from several groups, including our own, has shown
that several important pathogenic bacteria can modify their LPS or lipid A molecules
in ways that significantly alter TLR4 signaling to NFκB. Thus, it has been hypothesized
that expression of lipid A variants is one mechanism by which pathogens modulate or
evade the host immune response. Additionally, several key differences in the amino acid
sequences of human and mouse TLR4-MD-2 receptors have been shown to alter the
ability to recognize these variations in lipid A, suggesting a host-specific effect on the
immune response to these pathogens. In this review, we provide an overview of lipid A
variants from several human pathogens, how the basic structure of lipid A is recognized
by mouse and human TLR4-MD-2 receptor complexes, as well as how alteration of this
pattern affects its recognition by TLR4 and impacts the downstream immune response.
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INNATE IMMUNITY IN THE HOST
Innate immunity is the first line of defense against pathogens
and involves the recognition of pathogen-associated molecular
patterns (PAMPs), by pattern recognition receptors expressed
by the host cell. This initial recognition is crucially important
for the immediate innate immune response, and also for direct-
ing the later pathogen-specific adaptive immune response. While
these molecular patterns are considered to be relatively conserved
structures, there is in fact significant diversity within the basic
structural framework, and the ability to modify PAMPs may be
an important tool for pathogenic microorganisms to evade or
modulate immune responses.
LPS
Lipopolysaccharide (LPS) is a well-characterized PAMP found in
the outer leaflet of the outer membrane of most Gram-negative
bacteria. It has three regions (Figure 1), a lipid A molecule
(endotoxin), which anchors LPS in the outer membrane, a core
sugar consisting of 3-deoxy-D-manno-oct-2-ulosonic acid (Kdo)
moieties, and the O antigen, which consists of repeating oligosac-
charide units (Raetz andWhitfield, 2002). The lipid A component
of LPS is recognized by Toll-like receptor 4 (TLR4) and its
co-receptor MD-2 on host cells (Kawai and Akira, 2010).
LPS molecules, due to their amphiphilic nature, can form
aggregates in aqueous environments above a critical micellar con-
centration (Brandenburg and Seydel, 2010). The structure of
these aggregates is influenced by the shape of the individual LPS
molecules as well as environmental factors such as temperature
or pH; furthermore, the type of aggregate structure formed can
predict its level of biological activity (Brandenburg and Seydel,
2010). Lamellar aggregate structures, such as those formed by
cylindrically-shaped LPSmolecules, are associated with poor acti-
vation of TLR4, whereas cubic or hexagonal structures, such as
those formed by conical molecules, are highly active (Erridge
et al., 2002; Brandenburg and Seydel, 2010).
It is thought that monomeric LPS molecules are extracted
from supramolecular structures prior to presentation to MD-2
and TLR4 (Gioannini et al., 2004), however it is still a point of
debate whether the immunologically relevant unit of LPS, the
form which is recognized by the host, is the monomer or the
aggregate. Human pathogens have been shown to modify their
LPS in ways that affect its shape, aggregate structure, and thus
its ability to activate TLR4 (Zughaier et al., 2007). Although the
response to LPS aggregates cannot be overlooked, here, we have
focused on the interaction of monomeric LPS and TLR4.
TLR4
TLR4 is a member of the Toll-like receptor family. There are
10 known human TLRs which recognize distinct PAMPs. TLR1,
2, and 6 combine to recognize bacterial lipoproteins, TLR4
recognizes LPS, and TLR5 recognizes flagella; these TLRs are
expressed on the cell surface. TLR3, 7, 8, and 9 are found in
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FIGURE 1 | Schematic of the basic structure of lipopolysaccharide.
LPS consists of three regions: from the bottom, lipid A (chair structure
indicates di-glucosamine headgroup, red circles indicate phosphate
groups, squiggly lines indicate acyl chains), core sugars, and O-antigen,
which consists of repeating units (denoted in brackets, with an “n”) of
oligosaccharides.
endosomal compartments and recognize bacterial or viral nucleic
acids [reviewed in (Kawai and Akira, 2011)]. TLRs are type I
transmembrane proteins: they consist of an extracellular region
made up of conserved leucine-rich repeat (LRR) domains, which
recognize PAMPs, a transmembrane region, and the intracel-
lular region, which contains Toll/IL-1 receptor (TIR) signaling
domains needed to recruit adaptor proteins and facilitate signal-
ing [reviewed in (Kang and Lee, 2011)].
SIGNALING AND FUNCTIONAL CONSEQUENCES OF TLR4
RECOGNITION OF LPS
LPS is extracted from bacterial membranes by LPS binding pro-
tein (LBP) in serum. LBP then transfers LPS to CD14, which
can be found either in soluble form or linked to the cell
surface by a glycosyl-phosphatidylinositol (GPI) anchor. CD14
presents LPS to the TLR4 and MD-2 (TLR4-MD-2) receptor
complex. Upon binding LPS, the TLR4-MD-2 heterodimer is
thought to dimerize, which brings together their intracellular
TIR domains and creates a scaffold for the recruitment of adap-
tor proteins [reviewed in (Lu et al., 2008) and summarized in
Figure 2].
FIGURE 2 | Simplified diagram of signaling by LPS on host cells. LPS is
extracted from bacterial membranes by LPS binding protein (LBP) in serum,
passed to CD14, then transferred to MD-2 and TLR4, which form a complex
on the cell surface. LPS-induced receptor dimerization is followed by
recruitment of the adaptor proteins TIRAP and MyD88, which promotes
activation of the transcription factor NFκB. The TLR4-MD-2 complex can
also be internalized, which recruits a different set of adaptor proteins, TRIF
and TRAM, promoting activation of IRF3 and production of type I
interferons, as well as delayed activation of NFκB.
TLR4 can then signal via two distinct pathways, the MyD88-
dependent and TRIF-dependent pathways (Figure 2). In the
MyD88-dependent pathway, dimerization of TLR4-MD-2 at the
cell surface recruits the adaptor proteins TIRAP (MAL) and
MyD88 (Kagan and Medzhitov, 2006). This initiates a signaling
cascade that culminates in the activation of the transcription fac-
tor NFκB and the production of pro-inflammatory cytokines such
as TNFα and IL-6 (Takeuchi and Akira, 2010). TLR4 is addition-
ally internalized into endosomes where it recruits a different set of
adaptor proteins, TRAM and TRIF, which signal to the transcrip-
tion factor IRF3 and promote the production of type I interferons;
this pathway also leads to “late” activation of NFκB (Kawai
and Akira, 2011). The internalization of TLR4 into endosomes
and activation of the TRIF pathway is facilitated by the activa-
tion of phosphatidylinositol-3-OH kinase [PI(3)K], specifically
the p110δ isoform, which generates phosphatidylinositol-(3,4,5,)-
trisphosphate, or PIP3, and leads to the dissociation of TIRAP
from the plasma membrane, resulting in its degradation (Aksoy
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et al., 2012). Activation of the TRIF pathway via TLR4 internal-
ization and production of type I interferons is controlled by CD14
(Jiang et al., 2005; Zanoni et al., 2011). Although the TRIF path-
way is not always activated upon LPS stimulation, for example, in
cells which do not express CD14 (Zanoni et al., 2011), it makes
an essential contribution toward the stimulation of an appropri-
ate immune response. Inhibition of the p110δ isoform of PI(3)K
led to increased production of MyD88-dependent cytokines such
as TNFα and IL-6, lower production of TRIF targets such as IFNβ
and IL-10, and increased endotoxin-induced death (Aksoy et al.,
2012).
Mice deficient in TLR4 have an increased susceptibility to
infection with Gram-negative bacteria (O’Brien et al., 1980; Cross
et al., 1989), but excessive activation of NFκB can lead to septic
shock (Liu and Malik, 2006), and inappropriate TLR4 activation,
for example, by nickel ligands (Schmidt et al., 2010) or house-
dust-mite allergen Derp2, which is structurally and functionally
similar toMD-2 (Trompette et al., 2009), can lead to allergy. Thus,
the ability of TLR4 to recognize a variety of molecular patterns
within a “conserved” LPS signature is important for host defense,
but this same flexibility, if not controlled, leaves the host vulnera-
ble to excessive or unwanted inflammatory responses. Work over
the last two decades has revealed a complex interplay between
the ability of pathogens to modulate their lipid A molecules, and
the host’s ability to recognize and differentially respond to these
variant ligands.
E. coli LPS HAS BEEN USED AS A MODEL FOR LPS
RECOGNITION BY TLR4 ANDMD-2
Most of what is known about how lipid A in LPS is recognized by
the TLR4-MD-2 complex on animal cells has been studied using
hexa-acylated lipid A from Escherichia coli, which is a strong ago-
nist of TLR4 signaling. E. coli lipid A (Figure 3A) consists of a di-
glucosamine backbone, 1- and 4′-phosphate groups, and six fatty
acyl chains, of which four are directly linked to the glucosamine
head group at positions 2, 3, 2′ and 3′, and two are secondary
chains attached to the hydroxyl groups of the 2′- and 3′-linked
chains (R2′′ and R3′′, respectively). E. coli lipid A is synthesized
in a series of reactions catalyzed by genes in the Raetz path-
way. The first step is the acylation of UDP-N-acetylglucosamine
(UDP-GlcNAc) at the C-3 position by LpxA. Next, LpxC cat-
alyzes the deacetylation at C-2, followed by acylation of the
C-2 amide by LpxD to yield UDP-2,3-diacylglucosamine. This is
cleaved by the pyrophosphatase LpxH to release UMP and gen-
erate lipid X. Lipid X is then condensed with a second molecule
of UDP-2-3-diacylglucosamine by LpxB, forming a disaccharide,
diglucosamine-1-phosphate. LpxK then adds a phosphate group
at the C-4′ position to yield lipid IVA. A Kdo sugar group is added
at C-6′ by KdtA (orWaaA) and the final steps of lipid A biosynthe-
sis involve the addition of lauroyl and myristoyl groups by LpxL
and LpxM at positions C-2′ and C-3′, respectively, to yield lipid A
[reviewed in (Raetz and Whitfield, 2002)].
In the following section, the basic mechanism underlying
E. coli hexa-acyl lipid A recognition by the host (human) TLR4-
MD-2 receptor complex will be discussed. We have summarized
this in simplified cartoon form in Figure 4. Briefly, the lipid A
portion of LPS sits partially inside the co-receptor protein MD-2.
Both lipid A and MD-2 interact directly with TLR4. Upon lig-
and (lipid A) binding, this complex of TLR4 andMD-2 dimerizes
with a second TLR4-MD-2 complex, which facilitates signaling
to downstream effectors. Although many amino acid residues in
both TLR4 and MD-2 have been identified as contributing to
this interaction, we have focused on two key interfaces where
lipid A interacts with the second TLR4 molecule in the dimer-
ized complex in order to discuss the potential significance of
modification of the regions of lipid A found to interact at these
interfaces.
HOW DOES TLR4-MD-2 RECOGNIZE LIPID A?
TLR4 cannot recognize lipid A on its own, and requires MD-2
(Shimazu et al., 1999), with which it forms a stable 1:1 com-
plex (Kim et al., 2007). MD-2 consists of two anti-parallel beta
sheets which fold into a large open binding pocket lined with
hydrophobic amino acid residues: this pocket accommodates the
hydrophobic fatty acyl chains of lipid A (Figure 4). Furthermore,
there are charged residues at the opening of the pocket which
can interact with negatively-charged phosphate groups on the di-
glucosamine backbone (Park et al., 2009). Thus, the amphipathic
lipid A molecule is accommodated by hydrophobic and charged
regions in the MD-2 binding pocket. The interface between the
MD-2 co-receptor and TLR4 is made up of a network of hydrogen
bonds; mutations in amino acid residues in MD-2 that interact
with TLR4 (C95, C105, D99-101), as well as mutations in amino
acid residues in TLR4 that interact with MD-2 (C29 and C40),
disrupt this interaction (Re and Strominger, 2003; Nishitani et al.,
2006).
In the dimerized TLR4-MD-2 complex, several key interac-
tions at two defined interfaces have been identified (Figure 4).
The crystal structure of human TLR4-MD-2 receptor with E. coli
hexa-acyl LPS (Park et al., 2009) shows the formation of an m-
shaped multimer made up of two molecules of TLR4 and two
molecules of MD-2. E. coli lipid A is positioned in the hydropho-
bic pocket of MD-2 such that five of six acyl chains are completely
buried inside the pocket, and the 6th chain (the R2 chain, as
indicated in Figure 4) is partially exposed on the surface of
MD-2 (Park et al., 2009). This is the first interface important
for dimerization: the hydrophobic R2 chain forms hydrophobic
interactions with F440∗, F463∗, and L444∗ in the second TLR4
molecule (Park et al., 2009), hereafter referred to as TLR4∗. In
Figure 4, these amino acid residues would be found in the green
cloud labeled “neutral.” The so-called “phenylalanine loop” of
MD-2, around amino acid residue F126, undergoes a structural
shift upon ligand binding. Thus, hydrophilic residues in the F126
loop, and R90 inMD-2, can formhydrogen bonds and ionic inter-
actions with TLR4∗: these surround and support the hydrophobic
first dimerization interface (Park et al., 2009). The second dimer-
ization interface consists of hydrophilic interactions between the
1-phosphate of lipid A and positively-charged residues in TLR4∗,
(the yellow cloud labeled with a “+” sign in Figure 4). In order
for the acyl chains to fit inside the MD-2 binding pocket, the
phosphorylated diglucosamine backbone of lipid A is displaced
upwards by 5 Å, which allows the phosphate groups to inter-
act with positively-charged lysine and arginine residues in TLR4,
TLR4∗, andMD-2, as well as by making a hydrogen bond to S118
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FIGURE 3 | Continued
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FIGURE 3 | Chemical structure of lipid A molecules. (A) Hexa-acylated
lipid A from E. coli. Red numbers indicate carbon numbering. (B)
Hexa-acylated lipid A from Y. pestis grown at 27◦C. (C) Tetra-acylated
lipid A from Y. pestis grown at 37◦C. (D) Tetra-acylated lipid IVA, a
biosynthetic precursor of hexa-acylated lipid A. (E) The synthetic
molecule Eritoran. (F) Monophosphoryl lipid A (MPLA). (G)
Glucosamine-modified lipid A from B. pertussis (strain BP338, a Tohama
I derivative).
FIGURE 4 | Simplified diagram of TLR4-MD-2 receptor complex
dimerization upon ligation of hexa-acyl lipid A. The amphipathic lipid A
molecule consists of negatively-charged (indicated by a circle with a “−”
sign in it) phosphate groups and hydrophobic fatty acyl chains. The fatty acyl
chains sit inside the “binding pocket” structure of the MD-2 co-receptor
protein, which is lined with hydrophobic amino acid residues, while the
phosphate groups are engaged by charged amino acids in MD-2 at the
mouth of the pocket. In the next part of the figure, we show lipid A inside
the MD-2 pocket and also in contact with TLR4, with which it forms a 1:1
complex. Upon lipid A binding, this TLR4-MD-2 complex dimerizes with a
second complex. From this position, lipid A engages the TLR4 molecule in
the second complex (TLR4∗) at two main interfaces: the first is mediated by
interaction of the 6th acyl chain of lipid A (which is shown sticking out of
the pocket) with uncharged amino acids (cloud labeled “neutral”) on TLR4∗,
the second is mediated by interaction of the negatively-charged
1-phosphate (1-PO4) on lipid A with positively-charged amino acid residues
(cloud labeled “+”) on TLR4∗.
of MD-2 (Park et al., 2009). Notably, this mechanism is rela-
tively conserved between human and mouse TLR4-MD-2, both
of which are potently activated by hexa-acyl LPS (Ohto et al.,
2012a).
VARIATIONS IN LIPID A AFFECT ITS RECOGNITION
As lipid A is required for bacterial growth [Neisseria meningi-
tidis being a notable exception (van der Ley and Steeghs, 2003)],
its basic biosynthetic pathway is highly conserved among Gram-
negative bacteria (Raetz et al., 2007). Mutations in any of the
genes catalyzing the first seven steps in the Raetz pathway are
lethal in E. coli (Trent et al., 2006). Bacteria can also express
unique variants of this basic structure, which affect the host
immune response, for example, by modulating resistance to
host-derived cationic antimicrobial peptides (CAMPs), or by dif-
ferentially affecting host TLR4 signaling (Trent et al., 2006). As
an example, Helicobacter pylori is a widespread human pathogen
that lives in the gastric mucosa (Taylor and Blaser, 1991). It
expresses the canonical hexa-acyl lipid A structure only in minor
amounts; the major species is mono-phosphorylated, decorated
with a phosphoethanolamine group on the 1-phosphate, and has
only three or four acyl chains (Moran et al., 1997; Suda et al.,
1997, 2001). This structure of lipid A is much less stimulatory
for TLR4 than hexa-acyl lipid A from E. coli (Cullen et al., 2011)
and promotes resistance to the antimicrobial peptide polymyxin
(Tran et al., 2006).
It is now appreciated that pathogenic bacteria have evolved
numerous mechanisms for the modification of lipid A, includ-
ing the expression of enzymes to add or remove acyl chains,
phosphate groups, or catalyze the addition of chemical groups
onto the phosphates. The ability of Gram-negative bacteria
to respond to environmental signals by regulating the expres-
sion of lipid A modifying enzymes was initially described for
the human pathogen Salmonella enterica serovar Typhimurium
(S. Typhimurium); however, homologues for these enzymes, as
well as the resulting lipid A variants, have been described in other
human pathogens as well [reviewed in (Ernst et al., 2001; Miller
et al., 2005)].
Here, we will summarize how variations in lipid A structure
can affect its recognition by TLR4, broadly divided into modifi-
cations to the hydrophobic acyl chains at the first dimerization
interface, and modifications to the charged phosphate groups at
the second interface.
VARIATIONS IN LIPID A ACYL CHAINS AND THEIR EFFECT ON THE
HOST IMMUNE RESPONSE
Variation in the number of acyl chains in lipid A can impact sig-
naling through TLR4 and dramatically alter the host immune
response to the pathogen. LpxL and LpxM, as described earlier,
catalyze the final two steps in the Raetz pathway, the addition
of secondary acyl chains on lipid A. In E. coli, LpxL (also called
HtrB) catalyzes the addition of the C-2′ lauroyl group on lipid A
(Clementz et al., 1996). LpxL1 is a homologue of E. coli LpxL that
is expressed in N. meningitidis, and catalyzes the addition of the
C-2′ secondary lauroyl group (van der Ley et al., 2001).N. menin-
gitidis expresses a hexa-acylated lipid Awith secondary acyl chains
at the C-2 and C-2′ positions (Kulshin et al., 1992); however, inac-
tivating mutations in lpxL1 have been found in meningococcal
disease isolates of N. meningitidis (Fransen et al., 2009). LpxL1
mutants express penta-acylated lipid A and have a decreased
ability to stimulate the production of the pro-inflammatory
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cytokine TNFα in a human macrophage cell line (van der Ley
et al., 2001). Furthermore, penta-acylated N. meningitidis lipid
A has a decreased ability to induce human dendritic cell mat-
uration (measured by upregulation of co-stimulatory molecules
and production of cytokines such as TNFα, IL-12p70, and IL-10)
compared to wildtype hexa-acylated lipid A (Zughaier et al.,
2006; Steeghs et al., 2008), suggesting that inactivating muta-
tions in lpxL1 might represent an immune evasion strategy.
Penta-acylated structures were found to bind to human MD-2
with lower affinity than hexa-acylated structures (Zimmer et al.,
2007). However, while LPS from the lpxL1 mutant also induced
poorer NFκB activation in a reporter assay in HeLa cells, this
effect was only seen in cells expressing human, but not mouse,
TLR4 and MD-2 (Steeghs et al., 2008). In a similar vein, penta-
acylated LPS from an lpxL1 mutant could antagonize TNFα
production induced by E. coli LPS in human peripheral blood
mononuclear cells, but not in mouse macrophages (Sprong et al.,
2011).
LpxM (also called MsbB), which is not essential for growth in
E. coli (Karow and Georgopoulos, 1992), catalyzes the myristoyla-
tion of lipid A at the 3′ position and is important for generation of
hexa-acyl lipid A (Clementz et al., 1997). LpxM mutants in E. coli
produce predominantly penta-acylated lipid A (Clementz et al.,
1997), which does not activate NFκB in reporter assays or induce
TLR4 oligomerization in vitro (Tsuneyoshi et al., 2006). Similarly,
stimulation of a macrophage cell line with purified LPS from
Yersinia pestis strain KM218 lacking lpxM yielded reduced levels
of the pro-inflammatory cytokine TNFα compared to wildtype
(Feodorova et al., 2009). Mutants in S. enterica are poorer at stim-
ulating production of TNFα and IL-1β in mouse dendritic cells
at low multiplicities of infection (Kalupahana et al., 2003), and
mutants in Shigella flexneri induces less inflammation in the intes-
tine (D’Hauteville et al., 2002). Interestingly, the decreased ability
to stimulate TLR4 makes S. flexneri less pathogenic (D’Hauteville
et al., 2002); a similar trend was seen in E. coli, where lpxM muta-
tion is also sufficient to make clinical isolates of E. coli less lethal
in BALB/c mice (Kim et al., 2004).
Changes in acylation also affect TLR4 activation in Y. pestis,
whereby temperature-dependent expression of tetra-acyl lipid A
resulted in decreased stimulation of TLR4 (Kawahara et al., 2002).
At 27◦C, Y. pestis lipid A is hexa-acylated and modified by an
aminoarabinose group on the phosphate group (Figure 3B). At
37◦C (Figure 3C), Y. pestis expresses lipid A with only four acyl
chains and no aminoarabinose modification (Kawahara et al.,
2002). This occurs because the expression of the acyltransferase,
lpxP is temperature-sensitive in Y. pestis (Rebeil et al., 2006).
Tetra-acyl lipid A stimulated decreased production of the pro-
inflammatory cytokine TNFα downstream of TLR4, and this
effect was greater in human than mouse macrophages (Kawahara
et al., 2002), pointing to a host-specific contribution to the
response. Others have manufactured more strongly agonistic
LPS in Y. pestis by expressing lpxL from E. coli (Montminy
et al., 2006). This strain did not kill wildtype mice, but did
kill TLR4- or MD-2-deficient mice, suggesting that TLR4 recog-
nition of more immunostimulatory LPS was needed for the
generation of a protective immune response (Montminy et al.,
2006).
Recent work has shown that mice expressing human TLR4-
MD-2, as opposed to mouse TLR4-MD-2, have severely decreased
production of other pro-inflammatory cytokines, including IL-
12p40 and IL-6, and are more susceptible to Y. pestis infection
(Hajjar et al., 2012). Thus, at the body temperature of a human
host, Y. pestis expresses a form of lipid A that allows it to evade
the immune response in a species-dependent, TLR4-dependent
manner.
Lipid A modifying enzymes which catalyze the addition or
removal of acyl chains in response to environmental stimuli have
also been described. PagL catalyzes the removal of an R-linked 3-
hydroxymyristate from lipid A, and is under the control of the
PhoP/PhoQ regulon in S. Typhimurium (Trent et al., 2001a).
Deacylated lipid A from E. coli expressing PagL was found to
induce significantly less NFκB activation in a reporter assay com-
pared to unmodified lipid A (Kawasaki et al., 2004). Bordetella
pertussis expresses a penta-acylated lipid A (Caroff et al., 2000).
A mutant strain of B. pertussis was generated that expressed a
homologue of pagL from B. bronchiseptica; the lipid A from this
strain was found to consist mostly of tetra-acylated lipid A that
was missing the C-3 position hydroxymyristate (Geurtsen et al.,
2006). Stimulation of a human macrophage cell line with this
strain resulted in significantly decreased production of the pro-
inflammatory cytokine IL-6 (Geurtsen et al., 2006). Outer mem-
brane vesicles from this mutant strain, compared to wildytpe,
induced significantly lower expression of the cytokines IL-6 and
IL-1β in the lung following intranasal challenge in mice (Asensio
et al., 2011). Analysis of the bronchoalveolar lavage from infected
mice showed a decrease in the proportion of Gr-1+ neutrophils,
again suggesting a decrease in airway inflammation (Asensio
et al., 2011).
PagP adds a palmitate to the 2 position N-linked hydrox-
ymyristate of lipid A (Guo et al., 1998). In S. Typhimurium,
it is also regulated by the PhoP/PhoQ system and is impor-
tant for resistance to CAMPs (Guo et al., 1997). Expression of
S. Typhimurium PagP in E. coli generates hepta-acyl lipid A,
which had a reduced ability to activate NFκB in a luciferase
reporter assay (Kawasaki et al., 2005b). A homologue of PagP
has been described in B. bronchiseptica, where PagP expression
is controlled by the Bvg virulence regulon. B. bronchiseptica in
Bvg+ phase expresses a hexa-acylated lipid A, whereas a mutant
strain lacking pagP expresses a penta-acylated lipid A (Preston
et al., 2003). PagP is necessary for persistent colonization of the
mouse respiratory tract (Preston et al., 2003) and resistance to
serum-mediated killing (Pilione et al., 2004).
Palmitoylation of lipid A has also been described in
Pseudomonas aeruginosa (Ernst et al., 1999), although a PagP
homologue has not been found in P. aeruginosa, which suggests
the expression of an alternate enzyme with this function. P. aerug-
inosa is an opportunistic pathogen, and has been known to cause
chronic lung infections in cystic fibrosis (CF) patients (McIsaac
et al., 2012). While a laboratory-adapted strain of P. aeruginosa
was found to express penta-acylated lipid A, isolates from the air-
ways of CF patients had hexa-acyl lipid A, due to the addition of a
palmitate group (Ernst et al., 1999). Hexa-acylated LPS from CF
isolates induced higher levels of IL-8 in HUVEC cells compared
to penta-acylated LPS (Ernst et al., 1999). CF LPS also induced
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increased production of the pro-inflammatory cytokine TNFα
in THP-1 cells and higher levels of NFκB activity in a reporter
assay (Hajjar et al., 2002). Interestingly, these effects were species-
specific: cells expressing mouse TLR4-MD-2 responded equally
well to penta- and hexa-acylated structures (Hajjar et al., 2002).
LpxR is a 3′-O-deacylase which catalyzes the removal of
the 3′ acyloxyacyl group from lipid A and was first charac-
terized in S. Typhimurium (Reynolds et al., 2006). Mutants
in S. Typhimurium where lpxR was deleted induced increased
inducible nitric oxide synthase (iNOS) production by RAW264.7
macrophages, suggesting a negative effect of LpxR on TLR4
stimulation (Kawano et al., 2010). Orthologues of lpxRwere addi-
tionally identified in several other organisms, includingH. pylori,
as well as Y. enterocolitica, where LpxR activity was again corre-
lated with decreased TLR4 stimulation under certain conditions
(Reines et al., 2012).
Recently, glycine or di-glycine modification of lipid A has been
described in Vibrio cholerae (Hankins et al., 2012). The presence
of the glycine modification did not significantly impact TLR4
activation, but was important for polymyxin resistance, perhaps
by reducing the negative charge of the bacterial surface (Hankins
et al., 2012).
Although there are many examples of acyl chain modifica-
tion of lipid A, the mechanism by which changes in the num-
ber of these chains differentially affects TLR4 signaling has not
been fully elucidated. However, the species-specific nature of the
response has aided the development of this understanding. In the
next section, we will review crystal structure and biochemical evi-
dence that describes how the tetra-acyl precursor of lipid A, lipid
IVA, is recognized by human and mouse TLR4-MD-2 complexes.
HOW IS LIPID A WITH FEWER THAN 6 ACYL CHAINS RECOGNIZED?
The extracellular portion of TLR4, particularly in an 82-amino
acid hypervariable middle region, is poorly conserved across
species (Hajjar et al., 2002), which suggests there is increased
selective pressure for this region of TLR4 to “cope” with vari-
able ligand structure. Indeed, while hexa-acylated lipid A is a
potent agonist for both mouse and human TLR4, the tetra-
acylated precursor molecule generated during the course of the
biogenesis of lipid A, lipid IVA (Figure 3D), induces species-
specific TLR4 responses. Lipid IVA displays antagonist activity
for TLR4 signaling in cells expressing human TLR4 and MD-2,
but has agonist activity for mouse (Akashi et al., 2001) and
horse (Walsh et al., 2008) TLR4-MD-2. The generation of inter-
species chimeric TLR4 and MD-2 molecules which swap regions
important for recognition of lipid IVA have greatly contributed
to our understanding of how variation in lipid A is differ-
entially recognized (Muroi and Tanamoto, 2006; Walsh et al.,
2008).
The crystal structures of lipid IVA in complex with both
human TLR4-MD-2 (Ohto et al., 2007) and mouse TLR4-MD-2
(Ohto et al., 2012a) have been described. In both structures,
all four acyl chains sit inside the MD-2 binding pocket (Ohto
et al., 2007). This implies a loss of the first dimerization inter-
face, at which the acyl chain that sits outside of the pocket
interacts with TLR4∗. Furthermore, the size of the MD-2 bind-
ing pocket is unchanged regardless of whether it accommodates
four- or six-chain lipid A; thus, in the presence of hexa-acyl lipid
A, extra space is generated by pushing the diglucosamine back-
bone upwards, thereby contributing to the creation of the sec-
ond dimerization interface between positively-charged residues in
TLR4∗ and negatively-charged phosphate groups on lipid A. This
does not occur in the structure of lipid IVA and human MD-2
(Ohto et al., 2012a), and thus antagonistic lipid IVA occupies the
human TLR4-MD-2 complex without triggering dimerization.
However, lipid IVA is an agonist for mouse and horse TLR4-
MD-2 (Akashi et al., 2001; Walsh et al., 2008). Notably, unlike
in the human complex, lipid IVA and lipid A have the same
overall orientation in the mouse MD-2 binding pocket (Ohto
et al., 2012a): the diglucosamine backbone of lipid IVA is shifted
upward by about 4–7 Å, similar to lipid A. This was predicted
by Meng et al. using molecular docking software (Meng et al.,
2010b). The presence of a negatively-charged glutamate residue
(E122) at the mouth of the MD-2 binding pocket repulses the
negatively-charged phosphate group on lipid IVA, and pushes
the backbone upward (Meng et al., 2010b). This model was con-
firmed by the crystal structure (Ohto et al., 2012a), which shows
that indeed the first dimerization interface is preserved, as the
C3–C7 atoms of the R2 acyl chain of lipid IVA are exposed to
solvent and make van der Waals contacts with F438∗ of TLR4∗.
Furthermore, the two phosphate groups, which are important for
activation of TLR4-MD-2, make direct hydrogen bonds with both
TLR4 and TLR4∗. The 1-phosphate of lipid IVA was found to be
surrounded by positively-charged residues, K341, K360 in TLR4,
and K367∗, R434∗ in TLR4∗, and R90 inMD-2. The 4′-phosphate
was surrounded by K263, R266, K319, and R337 of TLR4. K367∗
and R434∗ were previously identified by site-directed mutage-
nesis to be important for lipid IVA-induced signaling through
mouse TLR4 (Meng et al., 2010a,b), and are located at the sec-
ond dimerization interface. Replacement of these with residues
found at equivalent positions in human TLR4 (E369 and Q436)
abolished the responsiveness of mouse TLR4-MD-2 to lipid IVA
(Meng et al., 2010b).
Differences in the amino acid residues in MD-2 also con-
tributed to the species-specific responses. In the antagonistic
structure of human TLR4-MD-2 with lipid IVA, lipid IVA was
confined more deeply in the hydrophobic cavity than in mouse.
This is likely due to interaction of the phosphate group with
K122 at the mouth of the human MD-2 binding pocket, which
was thought to stabilize an antagonistic orientation of lipid IVA
(Meng et al., 2010b), whereas the side chain of E122 in mouse
MD-2 is oriented away from lipid IVA (Ohto et al., 2012a).
Additionally, L125 of mouse MD-2 makes van der Waals con-
tacts with N415∗, M417∗, L442∗, and S443∗ of TLR4∗. L125 is
not conserved in human MD-2 (K125). Thus, while changes in
the number of acyl chains in lipid A affect its interaction with
TLR4 and/or MD-2, the net effect on receptor dimerization and
signaling through the TLR4-MD-2 complex is host-specific.
Crystal structure analysis of mouse TLR4-MD-2 in complex
with lipid IVA showed that the receptor was dimerized (2:2:2),
similar to lipid A, although in solution, mouse TLR4-MD-2 in
complex with lipid IVA forms only monomers, while lipid A
induced the formation of dimers (Ohto et al., 2012a). Here, the
authors postulated that while both are agonists, lipid IVA is a
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weaker agonist than lipid A, and therefore that the interaction
would not be strong enough to maintain dimer formation in
solution (Ohto et al., 2012a).
The synthetic molecule Eritoran (Figure 3E) is derived from
Rhodobacter sphaeroides LPS and was first investigated for its
potential as an anti-sepsis therapeutic due to its antagonistic
activity on TLR4 signaling in both mouse and human cells
(Mullarkey et al., 2003; Visintin et al., 2005). Like lipid IVA,
Eritoran also has only 4 acyl chains, all of which fit in the MD-2
binding pocket and take up 90% of its solvent-accessible space
(Kim et al., 2007). Two of the acyl chains (R2 and R3) are fully
extended in the pocket and two (R2′ and R3′) are bent in the
middle. In this conformation, the diglucosamine backbone of
Eritoran is fully exposed to solvent, and the two phosphate groups
form ionic bonds with multiple positively-charged residues at the
opening of the MD-2 pocket. Eritoran does not interact directly
with TLR4 and does not induce TLR4-MD-2 complex dimeriza-
tion, as measured by gel filtration chromatography (Kim et al.,
2007).
Taken together, these data show that changes in the number
of acyl chains on lipid A can affect both the first dimerization
interface, involving the fatty acyl chain of lipid A and hydrophobic
amino acid residues on TLR4∗, as well as the second dimerization
interface, involving the 1-phosphate of lipid A with positively-
charged amino acid residues on TLR4∗, due to changes in how
lipid A is positioned insideMD-2. Furthermore, differences in the
availability of charged amino acid residues in mouse and human
MD-2 and TLR4/TLR4∗ contribute to species-specific responses.
In the next section, we will review how the phosphate groups of
lipid A at the second dimerization interface can be varied, as well
as the effect of some of these modifications on the host immune
response.
VARIATIONS IN LIPID A PHOSPHATE GROUPS AND THEIR EFFECT ON
THE HOST IMMUNE RESPONSE
The importance of the phosphate groups on lipid A has been
investigated using monophosphoryl lipid A (MPLA), a syn-
thetic and less toxic derivative of lipid A from S. Typhimurium
(Figure 3F). MPLA stimulation yielded low levels of the pro-
inflammatory cytokine IL-6, but robust levels of IP-10, IFNβ,
and MCP-1 in bone marrow-derived macrophages (Mata-Haro
et al., 2007). This suggests that loss of the 1-phosphate group leads
to normal activation of the TRIF pathway and poor activation
of the MyD88 pathway (Mata-Haro et al., 2007). Thus, modifi-
cation of lipid A phosphorylation may represent an important
means of modulating the activation of TLR4 and the down-
stream immune response for therapeutic purposes. Interestingly,
an earlier study also showed that MPLA induced low levels of
interferon gamma, IL-12 p40 and p35, but robust levels of IL-10
in mouse macrophages cultures (Salkowski et al., 1997), perhaps
pointing to an additional, as yet uncharacterized, role for lipid
A modification in directing the downstream adaptive immune
response.
Recent work has demonstrated that host-specific differences in
TLR4 can affect responses to phosphorylation variants of lipid A.
Human polymorphisms in TLR4 have been reported, including
D299G and T399I (Arbour et al., 2000). D299G, in particular,
has been associated with susceptibility to septic shock (Lorenz
et al., 2002), airway hyporesponsiveness to inhaled endotoxin
(Arbour et al., 2000), and defects in the recruitment of MyD88
and TRIF upon treatment with E. coli LPS (Figueroa et al., 2012).
TheD299G polymorphism causes a structural change at a site dis-
tal to LPS binding (Ohto et al., 2012b) and D299G TLR4 showed
increased hyporesponsiveness to MPLA compared to E. coli lipid
A (Yamakawa et al., 2013). Thus, human polymorphisms in TLR4
could have a significant impact on TLR4-mediated immunity
against pathogens that express monophosphorylated species of
lipid A.
Interestingly, lipid A phosphorylation is modified in sev-
eral species, including P. gingivalis, where dephosphorylation of
lipid A was linked to significantly poorer NFκB activation and
additionally reduced affinity for antimicrobial peptides (Coats
et al., 2009a,b). Francisella novicida has been shown to express
a tetra-acylated (16 or 18C) lipid A, with just one phosphate
group (1-phosphate), which induces no TLR4 response, agonist
or antagonist, in either human or mouse macrophages (Hajjar
et al., 2006). This finding suggests it is not recognized by TLR4,
and the authors speculated that the effect might be upstream of
TLR4/MD-2, perhaps a defect in recognition by LBP or CD14.
The enzymes that catalyze the addition or removal of the phos-
phate groups of lipid A have been described in Francisella tularen-
sis and F. novicida: LpxE and LpxF are integral inner membrane
enzymes that dephosphorylate lipid A in the periplasmic leaflet
of the inner membrane. LpxE removes the 1-phosphate group
from penta- or hexa-acylated lipid A (Wang et al., 2004). LpxF
removes the 4′-phosphate group from penta- or tetra-acylated
lipid A (Wang et al., 2006).
Homologues of LpxE or LpxF are not known to natu-
rally occur in Salmonella, but expression of these enzymes
in S. Typhimurium led to the generation of mono-phosphate
or non-phosphorylated lipid A mutants. LPS purified from
these mutants induced reduced levels of the pro-inflammatory
cytokines IL-6, IL-1β, and TNFα in macrophage cell lines, and
orally-administered bacteria were attenuated for colonization in
BALB/c mice, although sufficiently immunogenic to protect the
host from challenge with wildtype S. Typhimurium (Kong et al.,
2012). Thus, mono-phosphorylated (or non-phosphorylated)
lipid A is less immunostimulatory for TLR4, but must non-
etheless induce some protective immunity. LpxT is an enzyme
that catalyzes the addition of a phosphate group to generate lipid
A 1-diphosphate (Touze et al., 2008). In its absence, lipid A under-
goes increasedmodification with phosphoethanolamine (Herrera
et al., 2010), which would lead to increased resistance to antimi-
crobial peptides. The effect of the extra phosphate group on
TLR4 activation has not been characterized, and its effect on the
pathogenicity of the bacterium, or the host immune response to
it, is unknown.
Several enzymes that modify lipid A via the addition of various
chemical groups have been described. ArnT adds a 4-amino-
4-deoxy-L-arabinose moiety to the 4′-phosphate group (Trent
et al., 2001b), which increases resistance to polymyxin B and
other CAMPs in S. Typhimurium (Gunn et al., 1998). The neu-
tral aminoarabinose moiety is thought to reduce the negative
charge on the bacterial membrane and thereby reduce the binding
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affinity for cationic peptides and killing. The Arn operon has been
found in E. coli, S. Typhimurium, and P. aeruginosa (Trent et al.,
2001b). The effect of the aminoarabinose moiety on TLR4 signal-
ing is unclear, as chemical removal of this group from lipid A from
P. aeruginosa does not yield any significant change in TLR4 activ-
ity (Hajjar et al., 2002). However, disruption of aminoarabinose
addition did negatively affect PagL deacylase activity (Kawasaki
et al., 2005a), suggesting a possible indirect effect of this modifi-
cation on TLR4 activation.
PmrC catalyzes the addition of a phosphoethanolamine group
to 1- or 4′-phosphates (Lee et al., 2004). It is induced by PmrA,
and is linked to resistance to CAMPs in S. enterica (Lee et al.,
2004). Blocking phosphoethanolamine addition in Neisseria gon-
orrhoeae (by inactivation of LptA, the enzyme catalyzing the addi-
tion of phosphoethanolamine in N. gonorrhoeae) was found to
increase susceptibility to polymyxin B and complement-mediated
killing (Lewis et al., 2009). LpxO (PagQ) incorporates a hydroxyl
group into 2-hydroxymyristate lipid A and is also under the con-
trol of PhoP/Q (Gibbons et al., 2000; Raetz, 2001). The effects of
these enzymatic modifications on signaling through TLR4 have
not been described.
Glucosamine modification of lipid A (Figure 3G) from B. per-
tussis strain BP338, a Tohama I derivative, by an ArnT ortholog
is critical for its agonist activity in cells expressing human
TLR4, although it is dispensable for cells expressing mouse TLR4
(Marr et al., 2010a). Mutants lacking glucosamine modification
induced significantly decreased levels of the pro-inflammatory
cytokines TNFα, IL-6, and IL-1β, as well as the TRIF-dependent
chemokines IP-10 and RANTES, in a human macrophage cell
line, and showed decreased activation of NFκB in reporter assays.
A different lipid A species from B. pertussis strain 18-323 is an
antagonist in humans and a poor agonist in mice (Marr et al.,
2010b). This lipid A is also not glucosamine modified, and fur-
thermore has a shorter (10 or 12C instead of 14C) R3′ acyl chain.
These data show that the addition of positively-charged chemical
groups can also contribute to differential signaling. Whether the
differences in acyl chain length in B. pertussis affect TLR4 sig-
naling through alteration of the first dimerization interface (acyl
chain and TLR4∗) or by altering the position of lipid A, and
thus the interaction of the 1-phosphate group with positively-
charged residues in TLR4∗ at the second dimerization interface, is
unclear.
CONCLUSION
Although much work has gone into characterizing various lipid A
species and the enzymes involved in their modification, the mech-
anism by which these changes are recognized by TLR4, one of the
very first steps of the host immune response to the pathogen, has
been limited to a few structures. The recent crystal structure anal-
yses of human andmouse TLR4/MD-2 receptors in complex with
lipid A, lipid IVA, and Eritoran have provided insight into how
differences in acyl chain numbers can affect the position of lipid
A in the MD-2 binding pocket, and how lipid A interacts with
TLR4 and TLR4∗ to induce receptor dimerization. Many more
questions remain to be answered; for example, how are lipid A
molecules with shorter acyl chains coordinated? How do mod-
ifications to phosphate groups affect TLR4 crosslinking? It has
been proposed that the addition of positively-charged chemical
moieties onto the phosphate groups functions to reduce the
negative charge of the outer membrane and thereby decreases sus-
ceptibility to CAMPs, but it is conceivable that positively-charged
groups might also affect how TLR4 recognizes lipid A, and this
has been demonstrated in the case of glucosamine modification
of B. pertussis lipid A (Marr et al., 2010a).
The relative contribution of each dimerization interface
involved in TLR4 recognition of hexa-acyl lipid A is unclear,
although mutational analysis has shown that both positively-
charged residues in TLR4∗, as well as the F440 residue in TLR4∗
that interacts with the R2 acyl chain of lipid A, are required
for optimal activation of NFκB (Resman et al., 2009; Meng
et al., 2011). Interestingly, loss of the 1-phosphate group on
MPLA results in preferential signaling through the TRIF, but not
MyD88-dependent pathway. The mechanism for how this might
occur is unclear. Gangloff has proposed a model whereby in
acidic endosomes (pH 5.5), the introduction of positive charges
on histidine residues in the extracellular domain of TLR4 leads
to the formation of an “alternative dimerization mode,” one that
would allow MPLA to signal in endosomes and activate the TRIF
pathway (Gangloff, 2012).
Clearly, much can still be gleaned from a more comprehen-
sive understanding of this interaction, especially as effects of
phosphatemodification on downstream immune responses (den-
dritic cell maturation, cytokine production, innate cell recruit-
ment, bacterial clearance) have been reported (Mata-Haro et al.,
2007), yet there is still little known about how changes in lipid
A engagement of TLR4, and the subsequent dimerization of
the TLR4-MD-2 complex, can lead to such diverse responses.
The potential importance of this understanding is highlighted
by a study that showed that various Gram-negative pathogens
can differentially stimulate the production of MyD88-dependent
and TRIF-dependent cytokines and chemokines (Zughaier et al.,
2005). Hexa-acylated LPS from E. coli and V. cholerae stimulated
robust TNFα, which could be inhibited by dominant negative
MyD88, but lower levels of nitrite or IP-10, typical indicators of
TRIF-pathway activation, compared to LPS from S. Typhimurium
or S. Minnesota. On the other hand, N. meningitidis, which
expresses a hexa-acylated LOS, produced robust levels of TNFα,
IP-10, and nitrite (Zughaier et al., 2005). A more complete
understanding of how lipid A variants affect TLR4 signaling is
expected to aid vaccine design, both for improving adjuvan-
ticity and for minimizing undesirable inflammatory responses,
as well as potentially providing insight into pathogen-specific
immunomodulation strategies. Interestingly, TLR4 has also been
shown to mediate LPS-induced autophagy in human and mouse
macrophages (Xu et al., 2007; Shi and Kehrl, 2008) and repeated
exposure to LPS induces tolerance in macrophages, monocytes, as
well as dendritic cells (Biswas and Lopez-Collazo, 2009). Both of
these LPS-induced responses have significant implications for the
host-pathogen interaction, but the effect of lipid A modification
is unknown.
Although this review focused on monomeric LPS (lipid A)
interactions with TLR4, the contribution of LPS aggregates
on the host response, perhaps upstream or independent of
LBP and CD14 (Sasaki and White, 2008), may also be an
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important consideration. In addition, previous work has sug-
gested that some LPS variants have a decreased ability to bind
CD14 or LBP, upstream of TLR4 (Cunningham et al., 1996;
Neumeister et al., 1998). The crystal structure of CD14 suggests
that lipid A may bind on a large hydrophobic face in the N-
terminal region of the molecule (Kim et al., 2005); however, it
is at present still unclear how lipid A modification may affect its
recognition and binding to CD14 or LBP.
Intriguingly, the ability of host TLR4-MD-2 complexes to dif-
ferentially respond to lipid A variants is, at least to some degree,
species-specific (Akashi et al., 2001; Hajjar et al., 2002, 2012;
Walsh et al., 2008; Marr et al., 2010a,b). Further analysis of how
different lipid A structures from Gram-negative pathogens are
recognized by host TLR4-MD-2 receptors is expected to provide
insight into how pathogens have evolved to fine tune the very
first step in their recognition by, and interaction with, host innate
receptors, and additionally how host receptors may have evolved
to respond to these pathogens.
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